CBPD-409

CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435) ; Blue: CRBN/cullin 4A Thalidomide (HY-14658) ; Black: Linker) [1].

Product Specifications

CAS Number

[3037549-86-0]

UNSPSC

12352005

Target

Histone Acetyltransferase; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cbpd-409.html

Purity

99.38

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1C2C(NC(CC2)=O)=O)C3=CC(N4CCN(C[C@@H]5CC[C@@H](N6C7=C(CN(C(C)=O)CC7)C(N8C9=C(CCC8)C=C(C(C(F)F)=C9)C%10=CN(C)N=C%10)=N6)CC5)CC4)=CC=C3C1=O

Molecular Formula

C46H52F2N10O5

Molecular Weight

862.97

References & Citations

[1]Chen Z, et al., Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. J Med Chem. 2024 Mar 26.